🇺🇸 RTXM83 in United States
6 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 6
Most-reported reactions
- Sepsis — 3 reports (50%)
- Death — 1 report (16.67%)
- Pulmonary Embolism — 1 report (16.67%)
- Respiratory Failure — 1 report (16.67%)
Other Oncology approved in United States
Frequently asked questions
Is RTXM83 approved in United States?
RTXM83 does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for RTXM83 in United States?
mAbxience Research S.L. is the originator. The local marketing authorisation holder may differ — check the official source linked above.